Exploring HIV-1 Maturation: A New Frontier in Antiviral Development
Author:
McGraw Aidan1ORCID, Hillmer Grace1, Medehincu Stefania M.1, Hikichi Yuta2, Gagliardi Sophia1, Narayan Kedhar1, Tibebe Hasset1, Marquez Dacia1, Mei Bose Lilia1, Keeting Adleigh1, Izumi Coco1ORCID, Peese Kevin3, Joshi Samit3, Krystal Mark3ORCID, DeCicco-Skinner Kathleen L.1ORCID, Freed Eric O.2ORCID, Sardo Luca3, Izumi Taisuke14ORCID
Affiliation:
1. Department Biology, College of Arts and Sciences, American University, Washington, DC 20016, USA 2. Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MS 21702, USA 3. ViiV Healthcare, 36 E. Industrial Road, Branford, CT 06405, USA 4. District of Columbia Center for AIDS Research, Washington, DC 20052, USA
Abstract
HIV-1 virion maturation is an essential step in the viral replication cycle to produce infectious virus particles. Gag and Gag-Pol polyproteins are assembled at the plasma membrane of the virus-producer cells and bud from it to the extracellular compartment. The newly released progeny virions are initially immature and noninfectious. However, once the Gag polyprotein is cleaved by the viral protease in progeny virions, the mature capsid proteins assemble to form the fullerene core. This core, harboring two copies of viral genomic RNA, transforms the virion morphology into infectious virus particles. This morphological transformation is referred to as maturation. Virion maturation influences the distribution of the Env glycoprotein on the virion surface and induces conformational changes necessary for the subsequent interaction with the CD4 receptor. Several host factors, including proteins like cyclophilin A, metabolites such as IP6, and lipid rafts containing sphingomyelins, have been demonstrated to have an influence on virion maturation. This review article delves into the processes of virus maturation and Env glycoprotein recruitment, with an emphasis on the role of host cell factors and environmental conditions. Additionally, we discuss microscopic technologies for assessing virion maturation and the development of current antivirals specifically targeting this critical step in viral replication, offering long-acting therapeutic options.
Funder
National Institutes of Health District of Columbia Center for AIDS Research
Reference260 articles.
1. HIV latency;Siliciano;Cold Spring Harb. Perspect. Med.,2011 2. Ta, T.M., Malik, S., Anderson, E.M., Jones, A.D., Perchik, J., Freylikh, M., Sardo, L., Klase, Z.A., and Izumi, T. (2022). Insights into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. Front. Microbiol., 13. 3. Sardo, L., Parolin, C., Yoshida, T., Garzino-Demo, A., and Izumi, T. (2021). Editorial: Novel Insights into a Functional HIV Cure. Front. Microbiol., 12. 4. HIV entry inhibitors: Mechanisms of action and resistance pathways;Briz;J. Antimicrob. Chemother.,2006 5. In PrEP: Long-acting antivirals for HIV prevention;Sharma;Cell Host Microbe,2022
|
|